Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 114,367 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 114,367 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dianthus Therapeutics Stock Up 1.7%

Shares of DNTH stock opened at $86.00 on Friday. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of -20.98 and a beta of 1.22. The stock has a fifty day moving average of $63.15 and a 200 day moving average of $47.62. Dianthus Therapeutics, Inc. has a 52 week low of $13.36 and a 52 week high of $88.49.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the business. Virtus Investment Advisers LLC grew its stake in shares of Dianthus Therapeutics by 7.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after buying an additional 416 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares in the last quarter. Royal Bank of Canada boosted its holdings in Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter worth $40,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research report on Monday, March 9th. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price for the company. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $117.30.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.